Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 454

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 454
---
2.0 years, (3) expected volatility of approximately 78% based on the trading history of
similar companies, and (4) zero expected dividends.

Common Stock – At the Market Offering

During March 2021, the Company entered into a
sales agreement (“Sales Agreement”) with BTIG, LLC (“BTIG”), as sales agent, to establish an At-The-Market (“ATM”)
offering program of up to $45 million of common stock, which the Company amended in August 2023. The Company was required to pay
BTIG a commission of 3% of the gross proceeds from the sale of shares. During the year ended December 31, 2024, the Company issued
and sold 198,364 shares of common stock at an average price of $10.56 per share under the ATM program. The aggregate net
proceeds were approximately $2.0 million after BTIG’s commission expenses.

During August 2024, the Company entered into an
amended and restated at-the-market sales agreement with RBC Capital Markets LLC and BTIG (together, the “Sales Agents”) relating
to the offer and sale of shares of our common stock with an aggregate offering price of up to $75.0 million. This amended and restated
at-the-market sales agreement replaced the Sales Agreement entered into with BTIG in March 2021, as amended in August 2023. The Company
is required to pay the Sales Agents a commission of 3% of the gross proceeds from the sale of shares. During
the year ended December 31, 2024, the Company issued and sold 48,762 shares of common stock at an average price of $6.96 per
share under the ATM program. The aggregate net proceeds were approximately $0.3 million after commission expenses. At December 31,
2024, the Company had $74.7 million of common stock available under the amended and restated at-the-market agreement.

During
July 2023, the Company sold 75,697 shares of its common stock at an average price of $10.56 per share under the ATM program.
The aggregate net proceeds were approximately $775,000 after offering expenses. These shares were inadvertently sold under a registration
statement filed with the SEC that had in fact expired prior to the time the shares were sold.   As of December 31,